You have 9 free searches left this month | for more free features.

Nonalcoholic fatty liver disease

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non-Alcoholic Fatty Liver Disease Trial in Seoul (GODEX, Placebo)

Enrolling by invitation
  • Non-Alcoholic Fatty Liver Disease
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 30, 2023

NAFLD Trial in Cairo (Lubiprostone 24Mcg Oral Cap)

Recruiting
  • NAFLD
  • Lubiprostone 24Mcg Oral Cap
  • Cairo, Egypt
    National Hepatology and Tropical Medicine Research Institute
Mar 2, 2023

Type 2 Diabetes, Non Alcholic Fatty Liver Disease Trial (Bempedoic acid)

Not yet recruiting
  • Type 2 Diabetes
  • Non Alcholic Fatty Liver Disease
  • Bempedoic acid
  • (no location specified)
Sep 14, 2023

Non-alcoholic Fatty Liver Disease Trial in Zagazig (Rybelsus Oral Product, Ozempic Injectable Product, Tocopherol and/or Actos)

Recruiting
  • Non-alcoholic Fatty Liver Disease
  • Rybelsus Oral Product
  • +2 more
  • Zagazig, Sharkia, Egypt
    Zagazig University
Apr 1, 2023

Heart Failure With Preserved Ejection Fraction, Non Alcoholic Fatty Liver Trial in Sohag (echocardiography)

Not yet recruiting
  • Heart Failure With Preserved Ejection Fraction
  • Non Alcoholic Fatty Liver
  • echocardiography
  • Sohag, El Monshah, Egypt
  • +1 more
Apr 7, 2023

NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis Trial (LUM-201)

Recruiting
  • NAFLD
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 26, 2022

Nonalcoholic Fatty Liver Disease Trial (Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver

Not yet recruiting
  • Nonalcoholic Fatty Liver Disease
  • Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
  • (no location specified)
Aug 8, 2022

Nonalcoholic Steatohepatitis, Genetic Risk Factor Trial (ALN-PNP Dose Level 1, ALN-PNP Dose Level 2, ALN-PNP Dose Level 3)

Not yet recruiting
  • Nonalcoholic Steatohepatitis
  • Genetic Risk Factor
  • ALN-PNP Dose Level 1
  • +3 more
  • (no location specified)
Sep 5, 2023

Observational Study About Patients Diagnosed With NAFLD

Recruiting
  • Nonalcoholic Fatty Liver Disease
    • Changsha, Hunan, China
      Department of Infectious Disease, Xiangya Hospital, Central Sout
    Nov 25, 2022

    Nonalcoholic Fatty Liver Disease Trial in Jerusalem (Anti-human CCL24 mAb (CM-101) - Part One, Anti-human CCL24 mAb (CM-101) -

    Completed
    • Nonalcoholic Fatty Liver Disease
    • Anti-human CCL24 monoclonal antibody (CM-101) - Part One
    • +3 more
    • Jerusalem, Israel
      Hadassah University Hospital - Ein Kerem
    Sep 13, 2023

    Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver

    Not yet recruiting
    • Nonalcoholic Fatty Liver Disease
    • Endoscopic Sleeve Gastroplasty
    • Morgantown, West Virginia
      West Virginia University
    Aug 16, 2022

    Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD Trial (Efinopegdutide, Semaglutide, Placebo)

    Not yet recruiting
    • Non-alcoholic Fatty Liver Disease
    • +4 more
    • (no location specified)
    May 17, 2023

    Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)

    Enrolling by invitation
    • Nonalcoholic Fatty Liver Disease
      • Nashville, Tennessee
        Vanderbilt University Medical Center
      Jul 5, 2022

      Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) Trial in Gainesville (Lanifibranor, Placebo)

      Recruiting
      • Nonalcoholic Fatty Liver Disease (NAFLD)
      • Type 2 Diabetes (T2DM)
      • Gainesville, Florida
        University of Florida
      Sep 20, 2022

      Weight Gain After Smoking Cessation and NAFLD

      Completed
      • Nonalcoholic Fatty Liver Disease
      • Type 2 Diabetes
        • Ningbo, Zhejiang, China
          Ningbo first hospital
        Sep 20, 2022

        Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Trial in Damanhur (Dapagliflozin 10mg Tab, Placebo)

        Recruiting
        • Nonalcoholic Fatty Liver Disease
        • Type 2 Diabetes
        • Dapagliflozin 10mg Tab
        • Placebo
        • DamanhÅ«r, Elbehairah, Egypt
          Rehab Hussein Werida
        Aug 11, 2022

        Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal Trial (Denosumab, Alendronate Sodium)

        Not yet recruiting
        • Nonalcoholic Fatty Liver
        • Osteoporosis, Postmenopausal
        • (no location specified)
        Aug 6, 2022

        Nonalcoholic Fatty Liver Disease in HIV Database

        Recruiting
        • NAFLD
        • +2 more
          • Birmingham, Alabama
          • +7 more
          Jan 11, 2023

          Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD Trial in San Antonio (AZD7503 Intervention)

          Active, not recruiting
          • Non-alcoholic Fatty Liver Disease
          • +5 more
          • AZD7503 Intervention
          • San Antonio, Texas
            Research Site
          Jan 13, 2023

          Type 2 Diabetes With Complication Trial in Xi'an (Canagliflozin, Pioglitazone)

          Recruiting
          • Type 2 Diabetes Mellitus With Complication
          • Xi'an, Shannxi, China
            First Affiliated Hospital Xi'an Jiaotong University
          Aug 22, 2022

          Type 2 Diabetes With Complication Trial (Canagliflozin, Pioglitazone)

          Not yet recruiting
          • Type 2 Diabetes Mellitus With Complication
          • (no location specified)
          Jul 5, 2022

          Hypercholesterolemia Trial (HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose)

          Not yet recruiting
          • Hypercholesterolemia
          • HSK31679 low dose
          • +4 more
          • (no location specified)
          Mar 20, 2023

          Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis Trial in Yokohama (Experimental: 4 mg/day of WY-8678 (guanabenz acetate),

          Active, not recruiting
          • Nonalcoholic Fatty Liver
          • Nonalcoholic Steatohepatitis
          • Experimental: 4 mg/day of WY-8678 (guanabenz acetate)
          • Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
          • Yokohama, Kanagawa, Japan
            Yokohama City University
          Sep 25, 2022

          Kuwait Adult Diabetes Epidemiological Multidisciplinary Program

          Recruiting
          • Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
          • +2 more
            • Kuwait City, Kuwait
              Dasman Diabetes Institute
            Oct 30, 2023

            PCOS, NAFLD, NASH Trial in San Francisco, Durham

            Recruiting
            • PCOS
            • +2 more
              • San Francisco, California
              • +1 more
              Nov 3, 2023